Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of Pamiparib (BGB-290) in Cancer Patients

Next Previous
Trial Profile

A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of Pamiparib (BGB-290) in Cancer Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary) ; Itraconazole; Rifampicin
  • Indications Advanced breast cancer; Colorectal cancer; Liposarcoma; Nasopharyngeal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
  • Focus Pharmacokinetics
  • Sponsors BeiGene

Most Recent Events

  • 12 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 16 Mar 2021 Planned End Date changed from 31 Mar 2021 to 2 Sep 2021.
  • 21 Dec 2020 Planned End Date changed from 1 Dec 2020 to 31 Mar 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top